Regulatory approvals are rejected and trials fail for a variety of reasons. It is the rule, not the exception in biotech. But I believe we have been making consistent progress in understanding the MOA of Leronlimab and its unexpected potential. I don’t believe our past failures are indicative of future failures. I like the way the Brazil trial is set up. If the molecule works the way we think it works, I think the trial will demonstrate it to the regulators’ satisfaction. I like Dr. Recknor’s understated professionalism. I like the timeline he gave for the BLA. I like the fact that he has met that timeline so far. In short, I think current management has planted enough seeds to produce a harvest this fall.

On the other hand, I think the alternative in 13d is a morass of corruption and competing interests. Not a single member inspires my confidence. I think their message board proxies are an odious bunch, hardly distinguishable — if there is any distinction at all — from the short selling cockroaches who have been maligning the company and the drug for all the years I have been here. Their entire campaign has been smug and repellent. Not only do I want them to lose the proxy battle, I would like to see them all in jail.